Matrine suppresses breast cancer metastasis by targeting ITGB1 and inhibiting epithelial‑to‑mesenchymal transition
Lili Ren(Nanjing Tech University), Xiaojia Wang(Wenzhou Medical University)
Cited by 27
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
FBI-1 enhanced the resistance of triple-negative breast cancer cells to chemotherapeutic agents via the miR-30c/PXR axis
|Cell Death and Disease|2020|42
PHF5A promotes colorectal cancer progression by alternative splicing of TEAD2
|Molecular Therapy — Nucleic Acids|2021|42
A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.
|Journal of Clinical Oncology|2022|36
miR‑519 regulates the proliferation of breast cancer cells via targeting human antigen�R
|Oncology Letters|2019|26